Remdesivir Risks: Doctor Challenges Protocol & Patient Safety
A recent social media exchange between Dr. William Makis, a physician, and Dr. Neil Stone has drawn attention to ongoing debate regarding treatment protocols for COVID-19. Dr. Makis, responding to a post by Dr. Stone, questioned whether Dr. Stone was administering Remdesivir to vulnerable patients, stating, “Shouldn’t you be killing a vulnerable patient with Remdesivir right now?”
The exchange highlights a continuing controversy surrounding the use of Remdesivir, an antiviral medication, in the treatment of COVID-19. Although Remdesivir has been authorized for emergency use by regulatory bodies, its efficacy and potential adverse effects remain subjects of debate within the medical community.
Research published in 2024 indicates a growing body of evidence suggesting potential adverse effects associated with both COVID-19 mRNA vaccination and coronavirus infection, potentially converging to cause extensive spike protein harms to the human body. A study available on ResearchGate details “Compound Adverse Effects of COVID-19 mRNA Vaccination and Coronavirus Infection.”
Further complicating the clinical picture, research into COVID-19 has revealed the role of neutrophil extracellular traps (NETs) in the disease’s progression. A 2019 article published in JCI Insight details how NETs, released by neutrophils to contain infections, can propagate inflammation and microvascular thrombosis in the lungs, particularly in patients with acute respiratory distress syndrome. The study found elevated levels of cell-free DNA and markers specific to NETs in the sera of COVID-19 patients, correlating with disease severity.
The use of lipid nanoparticles to target neutrophils and reduce lung injury and inflammation in SARS-CoV-2 infection is similarly being investigated, as noted in citations to the JCI Insight article. This research suggests a potential avenue for mitigating the inflammatory response associated with COVID-19.
Dr. Kathleen Ruddy, a cancer surgeon, has observed cases of cancer patients experiencing positive outcomes after taking ivermectin, leading her to launch a multicenter observational study on the impact of repurposed drugs on cancer survival rates. Dr. Ruddy stated, “I was as astonished as anyone might be that ivermectin has potential as an anti-cancer agent.” This research, reported by Peoples World War, explores the unexpected potential of an anti-parasitic medication in cancer treatment.
As of February 10, 2026, neither Dr. Stone nor the institutions with which he is affiliated have publicly responded to Dr. Makis’s statement.